Los Angeles Capital Management
LYEL icon

Los Angeles Capital Management’s Lyell Immunopharma LYEL Stock Holding History

Los Angeles Capital Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134K Buy
+9,505
New +$172K ﹤0.01% 1276

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Los Angeles Capital Management's LYEL Position: Q2 2026 in Review

Los Angeles Capital Management opened a new position in Lyell Immunopharma (LYEL) in Q2 2026: 9,505 shares worth $134K. The stake represents ﹤0.01% of the portfolio and ranks #1276 among its holdings.

87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Los Angeles Capital Management held 9,505 shares of Lyell Immunopharma worth $134K as of Q2 2026.
  • Lyell Immunopharma was a new Los Angeles Capital Management position in Q2 2026.
  • Lyell Immunopharma made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1276 holding.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.